Loading resource…

Vishal Patel, Antonio Salas, Thomas Grader-Beck
Despite significant advances in understanding Sjögren’s disease (SjD), there are currently no approved disease-modifying therapies. Management remains largely symptomatic, with off-label immunomodulators used for systemic features. The document discusses recent phase 2 and phase 3 trials that have shown promising efficacy signals, indicating a shift in the therapeutic landscape. It emphasizes the importance of trial design refinements and the need for targeted treatments to address the substantial unmet needs of patients.
No account needed